The role of alemtuzumab in the treatment of chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 175-176

  Zent, Clive S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CD52 ANTIGEN; CHLORAMBUCIL; PURINE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; HUMAN; HUMAN CYTOMEGALOVIRUS; INFECTION; INFECTION RISK; MONOTHERAPY; NEUTROPENIA; NONHUMAN; NOTE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 38849161398     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701809206     Document Type: Note

References (7)

1. Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D. and Munro, A. J. (1983) Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement. Blood, 62, pp. 873-882.
2. Mavromatis, B. and Cheson, B. D. (2003) Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol, 21, pp. 1874-1881.
3. Rodig, S. J., Abramson, J. S., Pinkus, G. S., Treon, S. P., Dorfman, D. M. and Dong, H. Y. (2006) Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res, 12, pp. 7174-7179.
4. Zent, C. S., Chen, J. B., Kurten, R. C., Kaushal, G. P., Lacy, H. M. and Schichman, S. A. (2004) Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res, 28, pp. 495-507.
5. Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P. A., Celsing, F. and Hjalmar, V. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, pp. 768-773.
6. Hui, D., Lam, W., Toze, C., Delorme, M., Noble, M., Klimo, P., Sutherland, J., Gill, K., Connors, J. and Sehn, L. (2008) Alemtuzumab in clinical practice: A British Columbia experience. Leuk Lymphoma, 49, pp. 218-226.
7. Fiegl, M., Falkner, A., Hopfinger, G., Brugger, S., Zabernigg, A. and Bauer, F. (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: A nation-wide retrospective study in Austria. Cancer, 107, pp. 2408-2416.